Teva Pharmaceuticals

Company Overview

Snapshot

Founded in January 1901, Teva Pharmaceuticals is a global pharmaceutical company with over 29,000 employees. The company has raised $908 million across multiple funding rounds from 5 investors. In March 2026, Teva secured a strategic funding agreement from Blackstone Life Sciences to advance the development of duvakitug, a monoclonal antibody for ulcerative colitis and Crohn's disease.

Business overview

Teva Pharmaceuticals is a global pharmaceutical company that develops, produces, and markets generic drugs, specialty pharmaceuticals, and active pharmaceutical ingredients. Headquartered in Israel, Teva's product portfolio includes over 3,600 medicines, manufacturing approximately 120 billion tablets and capsules annually across 70 facilities. The company operates in 60 countries and is ranked among the leading pharmaceutical companies worldwide, focusing on Health Tech & Life Sciences, particularly in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In June 2026, Teva Pharmaceuticals announced a restructuring of its raw materials unit, including layoffs of 250 employees in its active pharmaceutical ingredients (API) division in Israel. This move comes amid stalled revenues and a strategic review, signaling the company's efforts to optimize operations and adapt to market challenges, potentially impacting its future profitability and workforce strategy.

Company Intelligence Q&A

What recent strategic partnership did Teva Pharmaceuticals announce?

In March 2026, Teva Pharmaceuticals entered into a strategic funding agreement with Blackstone Life Sciences to advance the clinical development of duvakitug, a monoclonal antibody for ulcerative colitis and Crohn's disease. This $400 million investment supports Teva's 'Pivot to Growth' strategy, expanding its focus on higher-value branded therapies.

What was a significant product development for Teva Pharmaceuticals in early 2026?

In February 2026, Teva Pharmaceutical Industries announced that the FDA accepted its New Drug Application for olanzapine extended-release injectable suspension for schizophrenia treatment. This innovative formulation aims to improve treatment adherence and stability for patients, representing a significant step in addressing unmet needs in schizophrenia care.

What was the outcome of Teva's patent dispute with Corcept Therapeutics?

In February 2026, the United States Court of Appeals for the Federal Circuit ruled that Teva Pharmaceuticals' generic version of Korlym does not infringe on Corcept's patents. This decision upholds a previous verdict, allowing Teva to potentially market a generic version of the drug.

What was a key regulatory approval for Teva Pharmaceuticals in early 2025?

In May 2025, Teva Pharmaceutical Industries, in partnership with Alvotech, received FDA approval for SELARSDI™ (ustekinumab-aekn) as interchangeable with Stelara®. This approval expands SELARSDI's indications to include treatment for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, enhancing patient access to affordable treatment options.

What legal settlement did Teva Pharmaceuticals reach in late 2024?

In October 2024, Teva Pharmaceutical agreed to pay $450 million to settle allegations of submitting false claims and violating federal laws prohibiting kickbacks. This settlement resolved claims that Teva engaged in unlawful practices to promote its products and fix prices of generic drugs.